Get the App
Join our growing community to challenge mainstream media bias and fix the news
AbbVie to buy Botox maker Allergan for $63 billion

AbbVie to buy Botox maker Allergan for $63 billion

AbbVie is to buy Allergan for $63 billion, a move designed to diversify AbbVie’s drug lineup before Humira, its blockbuster immune disorder treatment, loses patent protection. AbbVie will pay $120.30 in cash and a portion of its stock for each Allergan share. That amounts to $188.24 per share, or a 45 per cent premium to Allergan’s closing price Monday.

Timothy
Timothy
.       .
. . 1 year

Evil corporations

Top in Business